Abnormal growth of cardiac fibroblasts is critically involved in the pathophysiology of cardiac hypertrophy/remodeling. Hexarelin is a synthetic growth hormone secretagogue (GHS), which possesses a variety of cardiovascular protective activities mediated via the GHS receptor (GHSR), including improving cardiac dysfunction and remodeling. The cellular and molecular mechanisms underlying the effect of GHS on cardiac fibrosis are however not clear. In this report, 
Introduction
Abnormal growth of cardiac fibroblasts is critically involved in the pathophysiology of cardiac remodeling induced by hypertension and myocardial ischemia/reperfusion injury (7) . Cardiac fibroblasts , which constitute 60% of the total heart cells, contribute to the pathologic structural changes in the heart by undergoing proliferation, deposition of extracellular matrix (ECM) proteins such as collagen, and replacing myocytes with fibrotic scar tissue (17) . Thus, fibroblastinduced cardiac remodeling may participate in diastolic and systolic dysfunction, leading to congestive heart failure (7).
Hexarelin is one of the synthetic growth hormone secretagogues (GHS). GHS possess strong growth hormone-releasing effects and other neuroendocrine activities, such as stimulatory effects on prolactin and adrenocorticotropic hormone secretion, and influence on sleep and food intake (21, 43). These activities are mediated by specific receptors, GHSR, which have also been identified in several peripheral tissues other than the hypothalamus-pituitary system, particularly in the myocardium, where they probably mediate GH-independent activities (36) . Recent evidence indicates that GHS feature a variety of cardiovascular activities, including increase of myocardial contractility (4, 5, 44) , improvement of left ventricular dysfunction and left ventricular pathological remodeling (6, 25, 34) , protection of cardiomyocytes from Angiotensin II (Ang II)-induced apoptosis (35) and myocardial infarction-or pressure overload-induced heart failure in vivo (33, 37, 45) . However, the cellular and molecular mechanisms underlying the effect of GHS on cardiac fibroblasts have not been investigated.
Using cultured 8-day-old rat cardiac fibroblasts, we tested whether hexarelin 1) inhibits cardiac fibroblast proliferation ( streptomycin, and 0.25 mg/L amphotericin B. Cell suspensions were passed through a 200µ mesh screen (Sigma) into a 100-mm culture dish and incubated for 45 minutes at 37°C. Unattached cells were discarded; attached cells were washed twice with 10% fetal calf serum (FCS)/DMEM and allowed to grow to confluence before passage in 1:3 dilutions of trypsin-based solution. All cells used in these experiments were taken from passage 2-3.
MTT assay
Fibroblast proliferation was evaluated by MTT assay, which is based on the transformation of tetrazolium salt MTT by active mitochondria to an insoluble formazan salt. Cardiac fibroblasts (plating density, 120 cells/mm 2 ) were treated in 96-well plates and grown until 70% to 80% confluent, synchronized in medium containing 0.1% FCS, and then stimulated to grow synchronously by adding 10 -7 mol/L Ang II to the culture medium. After 24 hours of treatment with and without hexarelin, MTT was added to each well under sterile conditions (with a final concentration of 0.5 mg/mL), and the plates were incubated for 4 h at 37°C. Untransformed MTT was removed by aspiration, and formazan crystals were dissolved in dimethyl sulfoxide (150 µL/well). Formazan was quantified spectroscopically at 540nm using a Bio-Rad automated EIA Analyzer (Bio-Rad Laboratories, USA). The experiments were performed in triplicate with different preparations of fibroblasts.
H-thymidine incorporation
Fibroblasts were seeded onto 24-well plates containing DMEM supplemented with 10% FCS at a density of 2×10 4 cells per well and allowed to grow until subconfluent, occupying 60% to 70% of the total surface of the plate. Cells were cultured in serum-free DMEM for 24 hours and then treated with 5% FCS either alone or combined with hexarelin (10 -7 mol/L). After 20 hours, the treatments were repeated with freshly prepared solutions but supplemented with 3 H-thymidine (1 mCi/mL, NEN) for an additional 4 hours.
The procedure for quantitating the incorporation of labeled thymidine was essentially as described by Itoh et al. (23) . At the end of the incubation period, the medium was aspirated, and the cells were washed twice with cold phosphate-buffered saline, pH 7.0, washed once with icecold 10% trichloroacetic acid, then incubated at 4°C for 30 minutes in 10% trichloroacetic acid.
Following aspiration, the cell residue was rinsed in 95% ethanol and dissolved in 0.25N NaOH at room temperature for 4 hours. After neutralizing with HCl, the radioactivity was measured by liquid scintillation spectrometry. Triplicate experiments were performed with different preparations of cells.
H-proline incorporation
Collagen synthesis by confluent cardiac fibroblasts was measured according to the method for 90 minutes at 37°C. The vials were placed on ice, and 0.5 mL of 20% TCA/0.5% tannic acid was added to precipitate protein for 1 hour. Supernatants were transferred to scintillation vials together with 0.5 mL 5% TCA after centrifugation at 10 000 rpm for 5 minutes. Scintillation fluid (10 mL) was added to each sample, and radioactivity was determined with a liquid scintillation counter. Triplicate experiments were performed with different cell preparations.
RT-PCR
Total RNA was isolated from cardiac fibroblasts by Trizol reagent (Gibco BRL, Life Technologies). Two µg of total RNA from each sample were reverse-transcribed into cDNA with SUPPERSCRIPT TM First-Strand Synthesis System (Gibco BRL). The PCR was performed as previously described (35) 
Measurement of cAMP level in cardiac fibroblasts
The fibroblasts were seeded onto 24-well plates containing DMEM supplemented with 10% FCS at a density of 2×10 4 cells per well and allowed to grow until sub-confluent. Cells were synchronized in medium containing 0.1% FCS and then stimulated by hexarelin at different concentrations. After incubation with hexarelin for 10 minutes, the cAMP level in cardiac fibroblast was determined by radioimmunassay. Brifly, the cells were lysed in 6% trichloroacetic acid, and the acid was removed by water-saturated diethyl ether extraction. After lyophilization of the aqueous phase, intracellular cAMP was measured with an RIA kit (Amersham, England).
Triplicate experiments were performed with different cell preparations.
Statistical Analysis
Data were expressed as mean ± SD, and differences in mean values were analyzed by student's t test and 1-way ANOVA with pair wise multiple comparisons and further analyzed by the Newman-Keuls method. P<0.05 was considered significant (compared with control unless otherwise specified).
Results

Hexarelin inhibited Ang II-stimulated proliferation of cardiac fibroblasts
Ang II (10 -7 mol/L) significantly increased the proliferation of cardiac fibroblasts compared with the negative control ( Figure 1 ). In Ang II-stimulated cells, co-treatment with hexarelin (from 10 In 5% serum-stimulated cells, hexarelin (10 -7 mol/L) significantly reduced the FCS-induced increase of 3 H-thymidine incorporation ( Figure 6A ). DMPX at 10 -7 mol/L almost abolished the inhibitory effect of hexarelin on the DNA synthesis of cardiac fibroblast compared with the control, while 10 -7 mol/L DPCPX had no effect on the inhibition of hexarelin ( Figure 6A ).
DPCPX or DMPX alone (10 -7 mol/L) did not significantly affect the FCS-induced increase of 3 H-thymidine incorporation ( Figure 6A ). The cAMP level in cardiac fibroblasts was significantly increased by hexarelin ( Figure 6B ). These results suggest that A 2 R mediates the inhibitory effect of hexarelin on cardiac fibroblast proliferation, possibly via the cAMP pathway, while A 1 R may not.
Discussion
Data presented here indicate that 1) hexarelin inhibits Ang II-and serum-induced rat cardiac fibroblast growth, proliferation, DNA synthesis and collagen synthesis; 2) the inhibitory effect of hexarelin is mediated through GHSR and A 2 R with a reduction of Ang II-induced TGFexpression and active TGF-1 release; and 3) cAMP is involved in the A 2 R-mediated inhibitory effect of hexarelin on cardiac fibroblast proliferation.
Hexarelin may alleviate cardiac fibrosis by reducing fibroblast proliferation and collagen syntheses
Cardiac fibrosis is a hallmark of heart disease and is the result of a variety of structural changes that occur after pathological stimuli to the cardiovascular system (27). The fibrosis is characterized by a disproportionate accumulation of fibrillar collagen that occurs after myocyte death, inflammation, enhanced workload, hypertrophy, and stimulation by a number of hormones, cytokines, and growth factors (3, 29, 30, 42) . The proximal effecter cells in this process are fibroblasts, which constitute the vast majority (>90%) of non-myocyte cells in the heart (17) . Cardiac fibroblasts increase the production of fibronectin and collagen when the heart is exposed to a variety of injuries, such as myocardial infarction, pressure overload, and myocarditis. It is believed that an increase in both the number of cardiac fibroblasts and the content of extracellular matrix proteins during cardiac remodeling is a major cause of cardiac dysfunction (9, 31, 32). receptors (14, 16). Tullin et al (41) reported that adenosine is an agonist of the growth hormone secretagogue receptor. Our study demonstrated that hexarelin dose-dependently increased the cellular level of cAMP in cardiac fibroblasts. Based on these findings, we speculate that the inhibitory effect of hexarelin on rat cardiac fibroblast proliferation is possibly partially mediated by the adenosine receptor. The present study showed that the specific A 2 R antagonist DMPX abolished the inhibitory effect of hexarelin on FCS-induced increase of DNA synthesis, while specific A 1 R antagonist DPCPX had no effect on these outcomes. These results suggest that the inhibitory effect of hexarelin on DNA and collagen production in rat cardiac fibroblasts is partially mediated by means of activating the A 2 R, possibly by the A 2B R subtype.
GHS, of which hexarelin is
The inhibitory effect of hexarelin on DNA and collagen synthesis in rat cardiac fibroblasts is associated with reduced TGF-expression and release in response to Ang II Ang II has a mitogenic effect in neonatal rat cardiac fibroblasts (38, 39) . Ang II also exerts mitogenic effects on adult cardiac fibroblasts (13). As in neonatal heart, Ang II increases mRNA levels for c-fos, c-jun, jun B, Egr-1, and c-myc in cardiac fibroblasts via AT1 receptor (38) .
Furthermore, Ang II increases collagen type I mRNA and the synthesis and secretion of collagen (13), as well as mRNA expression and protein secretion of fibronectin (24) . Ang II also increases cardiac fibroblast osteopontin expression and DNA synthesis that are completely blocked by antibodies against osteopontin and 3 integrin, suggesting that Ang II-induced cardiac fibroblast proliferation may require osteopontin engagement of 3 integrin (2) . In this experiment, we observed stimulation of cardiac fibroblast proliferation and collagen production by Ang II in vitro. In addition to these effects, Ang II increased cardiac fibroblast mRNA expression and protein secretion of transforming growth factor-1 (TGF-1) (11), which acted in synergy to interfere with the normal structure and function of the surrounding myocardium (11, 12, 28) .
TGF-has been implicated in several fibrotic disorders, including glomerulonephritis, liver cirrhosis, lung fibrosis, and vascular restenosis (8) . In vitro observations indicate that TGF-1 stimulates the expression of fibronectin and collagen and their incorporation into the ECM from cardiac fibroblasts (1, 18, 22, 40) , indicating that TGF-1 plays a crucial role in the myocardial remodeling process, particularly in cardiac fibrosis. The present studies show that administration of Ang II for 24h significantly increases mRNA expression of TGF-and active TGF-1 release from cardiac fibroblasts. However, hexarelin abolished Ang II-induced up-regulation of TGFexpression and active TGF-1 release. It is therefore suggested that the effect of hexarelin on collagen production in rat cardiac fibroblasts is associated with a decrease in Ang II-induced TGF-expression and active TGF-1 release.
In summary, hexarelin inhibits cardiac fibroblast proliferation and collagen synthesis. These inhibitory effects are mediated by A 2B R and probably also GHS-R, and associated with downregulation of TGF-expression. Our study suggests that the inhibitory effects of hexarelin on DNA and collagen synthesis in rat cardiac fibroblasts may be considered to be a new mechanism for hexarelin's protective effect on cardiac diseases. Hexarelin and 5% FCS-treated cells. 
